Dan Stanton

With over 30 years of scories experience at @Boehringer Uwr Buecheler talks paradigm shift in biologic manufacturing at ##BPIEUROPE in Vienna https://t.co/oiLY9AZQP6

Roche' Jose Ortiz Tena kicks off the manufacturing strategy track at #BPieurope saying this is the track where the upstream and downstream processes come together, with tech and data management ever more critical in the bioprocess space https://t.co/ZSQLBMs5Wl

On a plane headed to Vienna and missing the #BPIeurope predat workshops... however a little bird told me the Tech Transfer stream is at full capacity, which may shine some light on what tickles the bioprocess industry's tummy right now

On my way from Paris to Vienna Austria for another #BPIeurope and thanks to the good people at @AirFranceFR i'm about to enter the upstream!!! (That's a very weak bioprocess-y joke right there)

It's been a long time (pre Elon) since I've been on Twitter / X. Anyone still use this platform for #biopharma trade events eg #BPIeurope or is it just for MAGA lovers and culture wars?

Bringing the Pall portfolio under the Cytiva brand will bring customers simpler and greater access to bioprocess technologies and services, claims Danaher, though no comment on potential synergies and cost-savings. https://t.co/e7JWqM2wdT

Acquisition-hungry Danaher Corporation could continue to eye-up #CDMO opportunities despite reports it has given up on Catalent Pharma Solutions. Read my comment piece on why Danaher may be eying up other CDMO targets below https://t.co/x0VrodDhVD

The US FDA has approved Gamida Cell’s Omisirge (omidubicel), an allogeneic cell therapy for patients with blood cancers who are set to undergo stem cell transplantation. https://t.co/Pie3074bXq

Biogen will develop and commercialise an Alzheimer’s candidate using Denali’s Antibody Transport Vehicle (ATV)., writes reporter Anna Brown for BioProcess International https://t.co/TLyKNYXHeI

#CDMO Catalent’s stock price drops 26% as capacity ramp-up delays at a gene therapy plant in Maryland add to ongoing operational issues at sites in Indiana and Belgium. https://t.co/GZjadtJAow

Less than three years after Thermo Fisher launched cell therapy services from the site, the #cdmo is closing its Princeton, New Jersey facility citing changing manufacturing demands. https://t.co/QvkDeKyqAT

In what has become a highlight of Phacilitate’s #advancedtherapiesweek, @susanbnichols , chief business officer at ViroCell Biologics, highlighted 10 events from 2022 that drove conversation, investment, and innovation in the #cell…https://t.co/eZS6PtMk0k https://t.co/VLQ8S3eHi7

The cell and gene therapy pioneer and living legend Carl June just have a fantastic history of CAR-T and lessons learned since the first patients were dosed 10 years ago. so many takeaways but love the fact CAR-Ts were originally referred to as RAT-Ts !…https://t.co/FdM4za49uy

where are the opportunities for growth in cell amd gene therapy manufacturing? Dominic Clarke 's awesome slide at #atw2023 shows the main interlinking areas industry must embrace #advancedtherapiesweek https://t.co/TXePD6GM8r

where are the opportunities for growth in cell amd gene therapy manufacturing? Dominic Clarke 's awesome slide at #atw2023 shows the main interlinking areas industry must embrace #advancedtherapiesweek https://t.co/IOUh1aSpBU

With cell and gene therapies coming of age, experts at #advancedtherapiesweek looked to reducing COGs, novel payer models, and even biosimilars to tackle their spiraling price tags. Anthony Davies from Dark Horse Consulting Group…https://t.co/FVo0eGHTm3 https://t.co/F7nW666ePX

just about able to share this arbitrary 'I'm at Miami Beach' photo ahead of @phacilitate #AdvancedTherapiesWeek2023 - Full stories on @BioProInsider but prob less on Twitter as it seems to have gone caput (well done Musky!) at least on mobile https://t.co/dy4PN1XgP1